date,drug,stage,ticker
12/03/2017,ZX008 - (Study 1),Phase 3,ZGNX
12/04/2017,Larotrectinib (LOXO-101),Phase 2,LOXO
12/05/2017,SACTUZUMAB GOVITECAN (IMMU-132),Phase 3,IMMU
12/05/2017,Rilpivirine and Dolutegravir,PDUFA priority review,JNJ
12/05/2017,Semaglutide,PDUFA,NVO
12/07/2017,(Tucatinib ONT-380) and T-DM1,Phase 1b,CASC
12/09/2017,AFM13 with Keytruda,Phase 1b,AFMD
12/09/2017,Coversin,Phase 2,AKTX
12/09/2017,ARGX-110,Phase 2,ARGX
12/09/2017,ARGX-110,Phase 1/2,ARGX
12/09/2017,BPX-501,Phase 1/2,BLCM
12/09/2017,CB 2679d/ ISU304,Phase 1/2,CBIO
12/09/2017,JCAR017,Phase 1/2,CELG
12/09/2017,UCART19 (PALL),Phase 1,CLLS
12/09/2017,Flotetuzumab,Phase 1,MGNX
12/09/2017,SL-401,Phase 2,STML
12/09/2017,Sotatercept,Phase 2,XLRN
12/10/2017,AG-348,Phase 2,AGIO
12/10/2017,Actimab-A,Phase 2,ATNM
12/10/2017,LentiGlobin - HGB-206,Phase 1/2,BLUE
12/10/2017,CC-122,Phase 1/2,CELG
12/10/2017,CAEL‐101,Phase 1/2,FBIO
12/10/2017,G100,Phase 2,IMDZ
12/10/2017,KD025,Phase 2,KDMN
12/10/2017,Tipifarnib,Phase 2,KURA
12/10/2017,Tipifarnib,Phase 2,KURA
12/10/2017,SL-401,Phase 2,STML
12/10/2017,SL-401,Phase 2,STML
12/10/2017,TGR-1202,Phase 1/2,TGTX
12/11/2017,Ivosidenib,Phase 1,AGIO
12/11/2017,Ivosidenib,Phase 1,AGIO
12/11/2017,ALXN1210,Phase 1/2,ALXN
12/11/2017,bb2121,Phase 1,BLUE
12/11/2017,BLU-285,Phase 1/2,BPMC
12/11/2017,bb2121,Phase 1,CELG
12/11/2017,ProTmune - PROTECT,Phase 1/2,FATE
12/11/2017,GBT440 HOPE-KIDS 1,Phase 2a,GBT
12/11/2017,Imetelstat - IMerge Study,Phase 2/3,GERN
12/11/2017,GMI-1271,Phase 1/2,GLYC
12/11/2017,JCAR017,Phase 1/2,JUNO
12/11/2017,SPK-8011,Phase 1/2,ONCE
12/11/2017,TTI-621,Phase 1,TRIL
12/12/2017,Venclexta (MURANO),Phase 3,ABBV
12/12/2017,DARZALEX (Daratumumab) - ALCYONE,Phase 3,JNJ
12/15/2017,GR-MD-02,Phase 2b,GALT
12/24/2017,A-101,PDUFA,ACRS
12/26/2017,Twirla,PDUFA,AGRX
12/26/2017,Twirla,PDUFA,CORI
12/27/2017,Luminesse,PDUFA,VRX
12/30/2017,Macimorelin Acetate - Macrilen,PDUFA,AEZS
12/31/2017,Risankizumab,Phase 2b,ABBV
12/31/2017,CRS-207 with pembrolizumab,Phase 2,ADRO
12/31/2017,BAN2401 (Aβ mAb),Phase 2,BIIB
12/31/2017,Prexigebersen,Phase 2,BPTH
12/31/2017,Plinabulin (Trial 105),Phase 2/3,BYSI
12/31/2017,CB-839 with paclitaxel,Phase 2,CALA
12/31/2017,REVLIMID - RELEVANCE,Phase 3,CELG
12/31/2017,OTEZLA,Phase 2,CELG
12/31/2017,GED-0301,Phase 2,CELG
12/31/2017,CLR 131,Phase 2,CLRB
12/31/2017,Melphalan Hepatic Delivery System (Melphalan HDS),Phase 3,DCTH
12/31/2017,EG-1962,Phase 3,EDGE
12/31/2017,GS-9674,Phase 2,GILD
12/31/2017,IW-1973,Phase 2a,IRWD
12/31/2017,IW-1973,Phase 2,IRWD
12/31/2017,INVELTYS,Phase 3,KALA
12/31/2017,INVELTYS,Phase 3,KALA
12/31/2017,MGL-3196,Phase 2,MDGL
12/31/2017,Taksta - Fusidic acid,Phase 2/3,MLNT
12/31/2017,Ertugliflozin,PDUFA,MRK
12/31/2017,XMT1522,Phase 1,MRSN
12/31/2017,Indoximod + gemcitabine and nab-paclitaxel,Phase 2,NLNK
12/31/2017,NanoFlu vaccine,Phase 1/2,NVAX
12/31/2017,OCR-002,Phase 2a,OCRX
12/31/2017,AG013,Phase 2,OGEN
12/31/2017,Neratinib monotherapy with high dose loperamide prophylaxis - CONTROL,Phase 2,PBYI
12/31/2017,Xeljanz,Phase 3,PFE
12/31/2017,Ertugliflozin,Phase 3,PFE
12/31/2017,BOSULIF,PDUFA priority review,PFE
12/31/2017,Zepsyre(PM1183),Phase 3,PHMMF
12/31/2017,PTI-428,Phase 2,PTI
12/31/2017,RA101495,Phase 2,RARX
12/31/2017,Elacestrant,Phase 2b,RDUS
12/31/2017,Omaveloxolone - REVEAL,Phase 1/2,RETA
12/31/2017,RGX-501,Phase 1/2,RGNX
12/31/2017,Supinoxin,Phase 2a,RNN
12/31/2017,RX-3117,Phase 2,RNN
12/31/2017,Archexin,Phase 2a,RNN
12/31/2017,RT002 - SAKURA 2,Phase 3,RVNC
12/31/2017,RT002,Phase 2,RVNC
12/31/2017,RT002 - SAKURA 1,Phase 3,RVNC
12/31/2017,RXI-109-1402,Phase 2,RXII
12/31/2017,Samcyprone - RXI-SCP-1502,Phase 2,RXII
12/31/2017,SAGE-217,Phase 2,SAGE
12/31/2017,SAGE-217,Phase 2,SAGE
12/31/2017,TRC105,Phase 2,TCON
12/31/2017,HETLIOZ (tasimelteon),Phase 2,VNDA
01/07/2018,RESOLVE steroid-releasing implant,PDUFA,XENT
01/08/2018,Ubenimex - LIBERTY,Phase 2,EIGR
01/10/2018,AT132 - ASPIRO,Phase 1/2,BOLD
01/10/2018,Abemaciclib - MONARCH 1 and 2,PDUFA priority review,LLY
01/10/2018,LPCN 1021,PDUFA,LPCN
01/11/2018,Linhaliq (Pulmaquin),PDUFA priority review,ARDM
01/12/2018,Luxturna (voretigene neparvovec),PDUFA priority review,ONCE
01/15/2018,AXS-02 CREATE-1,Phase 3,AXSM
01/15/2018,AXS-02 COAST-1,Phase 3,AXSM
01/18/2018,BL-8040 in combination with KEYTRUDA - COMBAT trial,Phase 2,BLRX
01/19/2018,XL184 cabozantinib (CELESTIAL),Phase 3,EXEL
01/24/2018,Trulance (plecanatide),PDUFA,SGYP
01/26/2018,Lutathera,PDUFA,AAAP
01/28/2018,Lubiprostone,PDUFA,SCMP
01/31/2018,AST-OPC1 SCiSTAR,Phase 1/2,AST
01/31/2018,Intepirdine,Phase 2,AXON
01/31/2018,Intepirdine - HEADWAY-DLB,Phase 2b,AXON
01/31/2018,Nelotanserin,Phase 2,AXON
01/31/2018,KD025,Phase 2,KDMN
01/31/2018,Talazoparib,Phase 3,PFE
01/31/2018,ACE-083,Phase 2,XLRN
02/02/2018,Feraheme,PDUFA,AMAG
02/02/2018,Andexanet alfa,PDUFA,PTLA
02/03/2018,XGEVA,PDUFA,AMGN
02/12/2018,Bictegravir/F/TAF,PDUFA priority review,GILD
02/14/2018,Makena - auto injector,PDUFA,AMAG
02/14/2018,Makena - auto injector,PDUFA,ATRS
02/14/2018,EXPAREL,PDUFA,PCRX
02/15/2018,Cabozantinib - CABOSUN,PDUFA priority review,EXEL
02/15/2018,Tipifarnib,Phase 2,KURA
02/17/2018,Vitaros,PDUFA,APRI
02/23/2018,KP201/APAP,PDUFA,KMPH
02/28/2018,Rhopressa,PDUFA,AERI
02/28/2018,Lynparza,PDUFA priority review,AZN
02/28/2018,Neutrolin - LOCK-IT 100,Phase 3,CRMD
02/28/2018,IONIS-HTT Rx,Phase 1/2,IONS
02/28/2018,LJPC-501,PDUFA priority review,LJPC
02/28/2018,MGL-3196,Phase 2,MDGL
02/28/2018,Lynparza,PDUFA priority review,MRK
02/28/2018,Ganaxolone,Phase 2,MRNS
02/28/2018,IV Rigosertib - INSPIRE,Phase 3,ONTX
02/28/2018,RXI-109-1501,Phase 1/2,RXII
02/28/2018,ZTlido (lidocaine patch 1.8%),PDUFA,SRNE
02/28/2018,Tezacaftor (VX-661) / ivacaftor,PDUFA priority review,VRTX
03/02/2018,OTIPRIO,PDUFA,OTIC
03/05/2018,Opdivo -  4 week applications,PDUFA,BMY
03/13/2018,Xeljanz,PDUFA,PFE
03/30/2018,Natalizumab (α4-integrin inhibitor),Phase 2b,BIIB
03/31/2018,Gencaro - GENETIC-AF trial,Phase 2b,ABIO
03/31/2018,Tozadenant,Phase 3,ACOR
03/31/2018,AR101 PALISADE,Phase 3,AIMT
03/31/2018,NasoVAX,Phase 1/2,ALT
03/31/2018,ANB020,Phase 2a,ANAB
03/31/2018,Sollpura - RESULT,Phase 3,ANTH
03/31/2018,ARGX-113,Phase 2,ARGX
03/31/2018,APD371,Phase 2,ARNA
03/31/2018,Etrasimod,Phase 2,ARNA
03/31/2018,TIVO-3 - tivozanib,Phase 3,AVEO
03/31/2018,Nelotanserin,Phase 2,AXON
03/31/2018,Rimegepant,Phase 3,BHVN
03/31/2018,CM-227 – Opdivo + Yervoy,Phase 3,BMY
03/31/2018,Rezafungin (CD101) IV - STRIVE,Phase 2,CDTX
03/31/2018,REVLIMID - AUGMENT NHL-007,Phase 3,CELG
03/31/2018,CLBS03,Phase 2,CLBS
03/31/2018,Suprachoroidal CLS-TA - PEACHTREE,Phase 3,CLSD
03/31/2018,CORT125134,Phase 2,CORT
03/31/2018,CK-2127107,Phase 2,CYTK
03/31/2018,Olumacostat glasaretil (DRM01),Phase 3,DERM
03/31/2018,Keyzilen (AM-101) - TACTT3,Phase 3,EARS
03/31/2018,Bempedoic Acid - 1002-039,Phase 2,ESPR
03/31/2018,EGP-437,Phase 2b,EYEG
03/31/2018,Pamrevlumab (FG-3019),Phase 2,FGEN
03/31/2018,FLX-787 (Aust),Phase 2,FLKS
03/31/2018,NeuVax in combination with Herceptin,Phase 2b,GALE
03/31/2018,Imetelstat - IMbarkStudy,Phase 2,GERN
03/31/2018,GS-9674,Phase 2,GILD
03/31/2018,GS-9674,Phase 2,GILD
03/31/2018,Entospletinib,Phase 2,GILD
03/31/2018,Aramchol - ARRIVE,Phase 2,GLMD
03/31/2018,Dolutegravir + lamivudine (GEMINI 1),Phase 3,GSK
03/31/2018,Trilaciclib,Phase 2,GTHX
03/31/2018,GWP42006 (CBDV),Phase 2,GWPH
03/31/2018,IMM-124E,Phase 2,IMRN
03/31/2018,MB-102,Phase 1,MBIO
03/31/2018,MB-101,Phase 1,MBIO
03/31/2018,SER-262,Phase 1b,MCRB
03/31/2018,MPC-150-IM - Class IV,Phase 2b,MESO
03/31/2018,MSC-100-IV,Phase 3,MESO
03/31/2018,(MK-3475-189/KEYNOTE-189),Phase 3,MRK
03/31/2018,Mocetinostat and durvalumab,Phase 2,MRTX
03/31/2018,MYK-461 - PIONEER-HCM,Phase 2,MYOK
03/31/2018,OBE001 - IMPLANT2,Phase 2,OBSV
03/31/2018,OHR-102 (MAKO),Phase 3,OHRP
03/31/2018,Tanezumab,Phase 3,PFE
03/31/2018,Tanezumab,Phase 3,PFE
03/31/2018,OPRX-106,Phase 2,PLX
03/31/2018,PTG-100,Phase 2b,PTGX
03/31/2018,DTX301,Phase 1/2,RARE
03/31/2018,Praluent (alirocumab) ODYSSEY OUTCOMES,Phase 3,REGN
03/31/2018,Bardoxolone methyl - LARIAT,Phase 2,RETA
03/31/2018,Omaveloxolone - MOTOR,Phase 2,RETA
03/31/2018,RG-012,Phase 1/2,RGLS
03/31/2018,SAGE-217,Phase 2,SAGE
03/31/2018,Ezutromid,Phase 2,SMMT
03/31/2018,SAR439684 (PD-1),Phase 2,SNY
03/31/2018,Praluent (alirocumab) ODYSSEY OUTCOMES,Phase 3,SNY
03/31/2018,Topsalysin (PRX302),Phase 2,SPHS
03/31/2018,SPI-2012 (ROLONTIS),Phase 3,SPPI
03/31/2018,TRC105 and Inlyta,Phase 2,TCON
03/31/2018,Eravacycline (TP-434) - IGNITE3,Phase 3,TTPH
03/31/2018,VB-111,Phase 3,VBLT
03/31/2018,ASP0113 Vaccine,Phase 3,VICL
03/31/2018,Azeliragon - STEADFAST,Phase 3,VTVT
03/31/2018,ZGN-1061,Phase 2,ZFGN
04/03/2018,Ibalizumab,PDUFA,THERF
04/12/2018,Abemaciclib - MONARCH 3,PDUFA priority review,LLY
04/17/2018,KRN23 Burosumab,PDUFA priority review,RARE
04/17/2018,Fostamatinib,PDUFA,RIGL
04/27/2018,Elagolix,PDUFA priority review,ABBV
04/27/2018,Elagolix,PDUFA priority review,NBIX
04/30/2018,ALKS 3831 - ENLIGHTEN-2,Phase 3,ALKS
04/30/2018,KYPROLIS (ENDEAVOR),PDUFA,AMGN
04/30/2018,Selinexor - STORM,Phase 2b,KPTI
04/30/2018,Lefamulin - LEAP 2,Phase 3,NBRV
05/17/2018,Erenumab,PDUFA,AMGN
05/17/2018,Erenumab,PDUFA,NVS
05/26/2018,Intravenous (IV) meloxicam,PDUFA,REPH
05/28/2018,Prolia (denosumab),PDUFA,AMGN
05/31/2018,KIT-302,PDUFA,KTOV
06/18/2018,IDP-118,PDUFA,VRX
06/30/2018,Elagolix,Phase 3,ABBV
06/30/2018,Rova-T (TRINITY),Phase 2,ABBV
06/30/2018,ATI-50002,Phase 2,ACRS
06/30/2018,ATOGEPANT,Phase 2b,AGN
06/30/2018,UBROGEPANT,Phase 3,AGN
06/30/2018,ESMYA  (ulipristal acetate),PDUFA,AGN
06/30/2018,ALRN-6924,Phase 2a,ALRN
06/30/2018,ABP 798,Phase 3,AMGN
06/30/2018,ANB020,Phase 2a,ANAB
06/30/2018,Cingal,Phase 3,ANIK
06/30/2018,rocapuldencel-T (AGS-003) ADAPT Trial,Phase 3,ARGS
06/30/2018,Binimetinib - COLUMBUS,PDUFA,ARRY
06/30/2018,BTA074 5% topical gel,Phase 2,AVIR
06/30/2018,AXS-05 STRIDE-1,Phase 3,AXSM
06/30/2018,Selumetinib - ASTRA,Phase 3,AZN
06/30/2018,PT010,Phase 3,AZN
06/30/2018,Lynparza,Phase 3,AZN
06/30/2018,Durvalumab +/- tremelimumab (MYSTIC),Phase 3,AZN
06/30/2018,Durvalumab +/- tremelimumab (KESTREL),Phase 3,AZN
06/30/2018,Durvalumab +/- tremelimumab (EAGLE),Phase 3,AZN
06/30/2018,Durvalumab +/- tremelimumab (ARCTIC),Phase 3,AZN
06/30/2018,CM-651 – Opdivo + Yervoy,Phase 3,BMY
06/30/2018,CM-511 – Opdivo + Yervoy,Phase 3,BMY
06/30/2018,CM-451 – Opdivo + Yervoy,Phase 3,BMY
06/30/2018,CM-331– Opdivo,Phase 3,BMY
06/30/2018,CM-548 - Opdivo+SOC,Phase 2,BMY
06/30/2018,AT342 - VALENS,Phase 1/2,BOLD
06/30/2018,Glembatumumab vedotin,Phase 2b,CLDX
06/30/2018,Suprachoroidal CLS-TA - TYBEE,Phase 2,CLSD
06/30/2018,Suprachoroidal CLS-TA - HULK,Phase 1/2,CLSD
06/30/2018,Emricasan,Phase 2b,CNAT
06/30/2018,Corplex Donepezil,Phase 3,CORI
06/30/2018,Firdapse,Phase 3,CPRX
06/30/2018,PIXUVRI - PIX306 Trial,Phase 3,CTIC
06/30/2018,Viaskin Milk,Phase 2b,DBVT
06/30/2018,"Bempedoic acid - CLEAR LDL-C Lowering Program 1002-046, 1002-047 and 1002-048",Phase 3,ESPR
06/30/2018,Bempedoic acid (ETC-1002-040) - Clear Harmony,Phase 3,ESPR
06/30/2018,IMblaze370 - cobimetinib and atezolizumab,Phase 3,EXEL
06/30/2018,EGP-437,Phase 3,EYEG
06/30/2018,CEVA101,Phase 2,FBIO
06/30/2018,Pepvax vaccine,Phase 2,FBIO
06/30/2018,IV Tramadol,Phase 3,FBIO
06/30/2018,FLX-787,Phase 2,FLKS
06/30/2018,Gemcabene - INDIGO-1,Phase 2b,GEMP
06/30/2018,Filgotinib - EQUATOR,Phase 2,GILD
06/30/2018,Selonsertib (GS-4997),Phase 2,GILD
06/30/2018,Aramchol - ARREST,Phase 2b,GLMD
06/30/2018,Filgotinib - TORTUGA,Phase 2,GLPG
06/30/2018,Filgotinib - EQUATOR,Phase 2,GLPG
06/30/2018,G1T38 plus Faslodex,Phase 1b,GTHX
06/30/2018,IMO-8400,Phase 2,IDRA
06/30/2018,Epacadostat with Keytruda - ECHO-301,Phase 3,INCY
06/30/2018,Ruxolitinib - REACH 1,Phase 3,INCY
06/30/2018,JTX-2011,Phase 1/2,JNCE
06/30/2018,Esketamine,Phase 3,JNJ
06/30/2018,Tipifarnib,Phase 2,KURA
06/30/2018,MM-141 - CARRIE,Phase 2,MACK
06/30/2018,NexoBrid,Phase 3,MDWD
06/30/2018,Pracinostat in combination with Vidaza,Phase 2,MEIP
06/30/2018,Margetuximab in combination with pembrolizumab,Phase 2,MGNX
06/30/2018,MAT2501,Phase 2,MTNB
06/30/2018,Elagolix,Phase 3,NBIX
06/30/2018,LEE011: MONALEESA-3,Phase 3,NVS
06/30/2018,Neratinib,Phase 3,PBYI
06/30/2018,PF708 and Forteo,Phase 3,PFNX
06/30/2018,NEOD001 PRONTO,Phase 2b,PRTA
06/30/2018,PLX-PAD (stem cells),Phase 2,PSTI
06/30/2018,RX-3117 in combination with Abraxane,Phase 2a,RNN
06/30/2018,RXDX-105,Phase 1b,RXDX
06/30/2018,Setmelanotide,Phase 2,RYTM
06/30/2018,Setmelanotide,Phase 2,RYTM
06/30/2018,Setmelanotide,Phase 2,RYTM
06/30/2018,COR-003 (levoketoconazole) - SONICS,Phase 3,SBBP
06/30/2018,SB-525 cDNA gene therapy,Phase 1/2,SGMO
06/30/2018,SB-318,Phase 1/2,SGMO
06/30/2018,SB-FIX,Phase 1/2,SGMO
06/30/2018,SB-913 - CHAMPIONS,Phase 1/2,SGMO
06/30/2018,Entinostat plus Keytruda - ENCORE 601,Phase 1/2,SNDX
06/30/2018,E2112,Phase 3,SNDX
06/30/2018,SGX301 (synthetic hypericin),Phase 3,SNGX
06/30/2018,Aironite - INDIE,Phase 2,SVRA
06/30/2018,TD-9855,Phase 2a,TBPH
06/30/2018,TRC253,Phase 1/2,TCON
06/30/2018,TRC105 and Nexavar,Phase 2,TCON
06/30/2018,TG-1101 and TGR-1202 - UNITY-CLL study,Phase 3,TGTX
06/30/2018,TNX-102 SL,Phase 3,TNXP
06/30/2018,Toca 511 & Toca FC,Phase 2/3,TOCA
06/30/2018,Niraparib and Keytruda (TOPACIO),Phase 1/2,TSRO
06/30/2018,MitoGel - OLYMPUS,Phase 3,URGN
06/30/2018,VCL-HB01 HSV-2 Therapeutic Vaccine,Phase 2,VICL
06/30/2018,VK2809,Phase 2,VKTX
06/30/2018,AV-101,Phase 2,VTGN
06/30/2018,ZX008 - Study 1504,Phase 3,ZGNX
07/31/2018,Givosiran,Phase 3,ALNY
07/31/2018,BL-8040,Phase 2,BLRX
07/31/2018,Plinabulin (Trial 106),Phase 2/3,BYSI
07/31/2018,Luspatercept - BELIEVE,Phase 3,CELG
07/31/2018,Luspatercept - MEDALIST,Phase 3,CELG
07/31/2018,Vicinium,Phase 3,EBIO
07/31/2018,FMX103,Phase 3,FOMX
07/31/2018,FMX101 - FX2017-22,Phase 3,FOMX
07/31/2018,AEVI-001 (NFC-1),Phase 2,GNMX
07/31/2018,AEVI-002 (Anti-LIGHT mAb),Phase 1/2,GNMX
07/31/2018,Ramucirumab,Phase 3,LLY
07/31/2018,Sitravatinib plus nivolumab,Phase 2,MRTX
07/31/2018,OBE2109 - EDELWEISS,Phase 2b,OBSV
07/31/2018,RHB-104 MAP US,Phase 3,RDHL
07/31/2018,SCY-078 - oral,Phase 2,SCYX
07/31/2018,SNS-062,Phase 1/2,SNSS
07/31/2018,Tradipitant,Phase 2,VNDA
07/31/2018,Luspatercept - MEDALIST,Phase 3,XLRN
07/31/2018,Luspatercept - BELIEVE,Phase 3,XLRN
08/30/2018,Volanesorsen - APPROACH,PDUFA,AKCA
08/31/2018,Eculizumab,Phase 3,ALXN
08/31/2018,ImmunoPulse IL-12 - PISCES,Phase 2b,ONCS
09/30/2018,AEB1102,Phase 1/2,AGLE
09/30/2018,rAAV-hRS1,Phase 1/2,AGTC
09/30/2018,Vascepa REDUCE-IT outcomes trial,–,AMRN
09/30/2018,AQX-1125 LEADERSHIP,Phase 3,AQXP
09/30/2018,FLX-787 - COMMEND US trial,Phase 2,FLKS
09/30/2018,F/TAF (Descovy),Phase 3,GILD
09/30/2018,NeoCart,Phase 3,HSGX
09/30/2018,RG-012 - HERA,Phase 2,RGLS
09/30/2018,VTI-308,Phase 3,VTL
09/30/2018,AVP-786,Phase 3,CNCE
12/31/2018,ABT-494 - SELECT-COMPARE,Phase 3,ABBV
12/31/2018,Imbruvica - PHOENIX,Phase 3,ABBV
12/31/2018,"ARB-1467, tenofovir, and pegylated interferon",Phase 2,ABUS
12/31/2018,ACI-24 (anti-Abeta vaccine),Phase 1/2,ACIU
12/31/2018,ATI-50001,Phase 2,ACRS
12/31/2018,A-101,Phase 2b,ACRS
12/31/2018,ADVM-043,Phase 1/2,ADVM
12/31/2018,ADXS-PSA and Keytruda,Phase 1/2,ADXS
12/31/2018,Brazikumab,Phase 2b,AGN
12/31/2018,Cariprazine,Phase 3,AGN
12/31/2018,ABICIPAR,Phase 3,AGN
12/31/2018,Vadadustat - TRILO2GY,Phase 3,AKBA
12/31/2018,Vadadustat - FO2RWARD,Phase 2,AKBA
12/31/2018,AKCEA-APO(a)-LRx,Phase 2b,AKCA
12/31/2018,ADX-102,Phase 2b,ALDX
12/31/2018,ADX-102,Phase 3,ALDX
12/31/2018,ADX-102,Phase 2,ALDX
12/31/2018,ALN-CC5 (cemdisiran),Phase 1/2,ALNY
12/31/2018,ARGX-113,Phase 2,ARGS
12/31/2018,ARGX-113,Phase 2,ARGX
12/31/2018,Oraxol,Phase 3,ATNX
12/31/2018,Voclosporin,Phase 2,AUPH
12/31/2018,Voclosporin,Phase 2,AUPH
12/31/2018,Farxiga - DECLARE,Phase 3,AZN
12/31/2018,Benralizumab - TERRANOVA,Phase 3,AZN
12/31/2018,Farxiga - DECLARE,Phase 3,AZN
12/31/2018,Durvalumab +/- tremelimumab (NEPTUNE),Phase 3,AZN
12/31/2018,Anifrolumab,Phase 3,AZN
12/31/2018,Raxatrigine - BIIB074 (Nav1.7 inhibitor),Phase 2,BIIB
12/31/2018,INOpulse delivery device,Phase 2,BLPH
12/31/2018,INOpulse delivery device,Phase 3,BLPH
12/31/2018,BL-8040,Phase 2b,BLRX
12/31/2018,CM-602 – Opdivo + Elo + SOC,Phase 3,BMY
12/31/2018,CM-459 – Opdivo,Phase 3,BMY
12/31/2018,Plinabulin,Phase 3,BYSI
12/31/2018,REVLIMID - ROBUST,Phase 3,CELG
12/31/2018,MM-007 OPTIMISMM,Phase 3,CELG
12/31/2018,Oral Azacitidine - CC-486-AML-001,Phase 3,CELG
12/31/2018,ABRAXANE - PANC-003 apact,Phase 3,CELG
12/31/2018,ABRAXANE - IMpower 130 ( I/O Combo),Phase 3,CELG
12/31/2018,ABRAXANE - IMpower 131 ( I/O Combo),Phase 3,CELG
12/31/2018,ABRAXANE - IMPassion ( I/O Combo),Phase 3,CELG
12/31/2018,CF-301,Phase 2,CFRX
12/31/2018,Emricasan,Phase 2,CNAT
12/31/2018,CTP-543,Phase 2a,CNCE
12/31/2018,Exendin 9-39,Phase 2,EIGR
12/31/2018,Ubenimex - ULTRA,Phase 2,EIGR
12/31/2018,Tazemetostat,Phase 2,EPZM
12/31/2018,Bempedoic Acid/ Ezetimibe (1002FDC-053),Phase 3,ESPR
12/31/2018,Roxadustat - ANDES,Phase 3,FGEN
12/31/2018,Gemcabene - AZURE-1,Phase 2,GEMP
12/31/2018,GS-9876,Phase 2,GILD
12/31/2018,GS-5734,Phase 2,GILD
12/31/2018,Axicabtagene ciloleucel - KTE-C19 (ZUMA-2),Phase 2,GILD
12/31/2018,Axicabtagene ciloleucel - KTE-C19 (ZUMA-3),Phase 1/2,GILD
12/31/2018,Axicabtagene ciloleucel - KTE-C19 (ZUMA-4),Phase 1/2,GILD
12/31/2018,Closed Triple - CAPTAIN,Phase 3,GSK
12/31/2018,Enobosarm,Phase 2,GTXI
12/31/2018,Epidiolex,Phase 3,GWPH
12/31/2018,PEGPH20 - HALO-301,Phase 3,HALO
12/31/2018,Kadcyla (KATHERINE).,Phase 3,IMGN
12/31/2018,IMM-529,Phase 1/2,IMRN
12/31/2018,Closed Triple,Phase 3,INVA
12/31/2018,LN-145,Phase 2,IOVA
12/31/2018,STELARA (USTEKINUMAB),Phase 3,JNJ
12/31/2018,Selinexor - SADAL,Phase 2b,KPTI
12/31/2018,Flortaucipir F 18 (Tau imaging agent),Phase 3,LLY
12/31/2018,MM-121,Phase 2,MACK
12/31/2018,Annamycin,Phase 1/2,MBRX
12/31/2018,Epacadostat with Keytruda - ECHO-301,Phase 3,MRK
12/31/2018,Ganaxolone,Phase 2,MRNS
12/31/2018,INGREZZA - T-Force GOLD,Phase 2b,NBIX
12/31/2018,Tumor Treating Fields (TTFields) STELLAR,Phase 2,NVCR
12/31/2018,QVM149,Phase 3,NVS
12/31/2018,OBE022 - PROLONG,Phase 2a,OBSV
12/31/2018,OTX-TP,Phase 3,OCUL
12/31/2018,Tanezumab,Phase 3,PFE
12/31/2018,PRX-102,Phase 3,PLX
12/31/2018,QR-010,Phase 1/2,PRQR
12/31/2018,PUR1800,Phase 2,PULM
12/31/2018,RHB-105 - ERADICATE Hp 2,Phase 3,RDHL
12/31/2018,Bardoxolone methyl - CATALYST,Phase 3,RETA
12/31/2018,Fostamatinib,Phase 2,RIGL
12/31/2018,COR-003 (levoketoconazole) - LOGICS,Phase 3,SBBP
12/31/2018,ADCETRIS in combination with chemotherapy - ECHELON-2,Phase 3,SGEN
12/31/2018,SNA-001,Phase 3,SNNA
12/31/2018,SNA-001,Phase 3,SNNA
12/31/2018,Molgradex - IMPALA,Phase 3,SVRA
12/31/2018,Closed Triple - CAPTAIN,Phase 3,TBPH
12/31/2018,TRC105,Phase 2,TCON
12/31/2018,TRC102,Phase 2,TCON
12/31/2018,TRC105 (TAPPAS),Phase 3,TCON
12/31/2018,Esuberaprost - BEAT,Phase 3,UTHR
12/31/2018,Orenitram,Phase 3,UTHR
12/31/2018,HETLIOZ (tasimelteon),Phase 3,VNDA
12/31/2018,RPL554,Phase 2b,VRNA
12/31/2018,AV-101,Phase 2,VTGN
12/31/2018,XBIO-101,Phase 2,XBIT
12/31/2018,XmAb5871,Phase 2,XNCR
03/31/2019,Suprachoroidal CLS-TA - SAPPHIRE,Phase 3,CLSD
03/31/2019,ThermoDox - OPTIMA,Phase 3,CLSN
03/31/2019,Danirixin,Phase 2b,GSK
03/31/2019,Vonapanitase (PRT-201) PATENCY-2,Phase 3,PRTO
06/30/2019,ABBV-8E12,Phase 2,ABBV
06/30/2019,Iomab-B,Phase 3,ATNM
06/30/2019,CM-568 - Opdivo + Yervoy,Phase 2,BMY
06/30/2019,Emricasan,Phase 2,CNAT
06/30/2019,CEVA101,Phase 2,FBIO
06/30/2019,GBT440 - HOPE,Phase 3,GBT
06/30/2019,Tapinarof,Phase 3,GSK
06/30/2019,Inhaled PI3Kδ inhibitor,Phase 2b,GSK
06/30/2019,Ocaliva (Obeticholic acid (OCA)) - REGENERATE,Phase 3,ICPT
06/30/2019,Setmelanotide,Phase 3,RYTM
06/30/2019,Entinostat plus Tecentriq - ENCORE 603,Phase 1/2,SNDX
06/30/2019,SNA-120,Phase 2b,SNNA
06/30/2019,Telavancin,Phase 3,TBPH
07/31/2019,Vadadustat - INNO2VATE,Phase 3,AKBA
07/31/2019,Vadadustat - PRO2TECT,Phase 3,AKBA
10/31/2019,Fitusiran (ATLAS),Phase 3,ALNY
12/31/2019,Venetoclax,Phase 3,ABBV
12/31/2019,AFM13,Phase 2,AFMD
12/31/2019,RAPASTINEL,Phase 3,AGN
12/31/2019,ANB020,Phase 2b,ANAB
12/31/2019,AZD3293,Phase 3,AZN
12/31/2019,Durvalumab +/- tremelimumab (DANUBE),Phase 3,AZN
12/31/2019,Brilinta (THEMIS),Phase 3,AZN
12/31/2019,NurOwn,Phase 3,BCLI
12/31/2019,Valoctocogene roxaparvovec (BMN 270),Phase 3,BMRN
12/31/2019,Vosoritide,Phase 3,BMRN
12/31/2019,REVLIMID - MAGNIFY NHL-010,Phase 3,CELG
12/31/2019,Mycapssa - OPTIMAL,Phase 3,CHMA
12/31/2019,Emricasan,Phase 2b,CNAT
12/31/2019,Anabasum (Resunab),Phase 3,CRBP
12/31/2019,NeuVax in combination with Herceptin,Phase 2,GALE
12/31/2019,Mepolizumab - SYNAPSE,Phase 3,GSK
12/31/2019,Kadcyla (KAITLIN),Phase 3,IMGN
12/31/2019,Ruxolitinib - REACH 3,Phase 3,INCY
12/31/2019,INVOKANA - CREDENCE,Phase 3,JNJ
12/31/2019,DARZALEX (Daratumumab),Phase 3,JNJ
12/31/2019,Selinexor - SEAL,Phase 2/3,KPTI
12/31/2019,Selinexor - BOSTON,Phase 3,KPTI
12/31/2019,Inclisiran,Phase 3,MDCO
12/31/2019,MK-8931 (019) - Verubecestat,Phase 3,MRK
12/31/2019,QAW039 (fevipiprant),Phase 3,NVS
12/31/2019,OMB157 (ofatumumab),Phase 3,NVS
12/31/2019,Entresto - PARAGON,Phase 3,NVS
12/31/2019,Entresto - PARADISE,Phase 3,NVS
12/31/2019,AIN457 (Cosentyx),Phase 3,NVS
12/31/2019,OBE2109 - PRIMROSE,Phase 3,OBSV
12/31/2019,Bardoxolone methyl - CARDINAL,Phase 3,RETA
12/31/2019,Omaveloxolone - MOXIe,Phase 2,RETA
06/30/2020,ABBV-8E12,Phase 2,ABBV
06/30/2020,Axalimogene filolisbac - AIM2CERV Trial,Phase 3,ADXS
12/31/2020,RELAMORELIN,Phase 3,AGN
12/31/2020,Durvalumab (ADJUVANT),Phase 3,AZN
12/31/2020,Edasalonexent (CAT-1004),Phase 3,CATB
12/31/2020,REVLIMID - MAGNIFY NHL-008,Phase 3,CELG
12/31/2020,Mycapssa - MPOWERED,Phase 3,CHMA
12/31/2020,Daprodustat - ASCEND-D,Phase 3,GSK
12/31/2020,Ruxolitinib - REACH 2,Phase 3,INCY
12/31/2020,Tumor Treating Fields (TTFields) METIS,Phase 3,NVCR
12/31/2020,Ruxolitinib - REACH 2,Phase 3,NVS
12/31/2020,XTANDI,Phase 3,PFE
12/31/2020,NEOD001 VITAL,Phase 3,PRTA
06/30/2021,XTANDI (EMBARK),Phase 3,PFE
12/31/2021,Tumor Treating Fields (TTFields) LUNAR,Phase 3,NVCR
12/31/2023,CNP 520,Phase 2/3,NVS
